Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.51 |
| ▸ | GNPAT | O15228 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24642916 | 0.88 | DPP4 (0.41) | NOD1GNPATFOLH1DPP8DPP7 | |
| SCHEMBL29368554 | 0.82 | FOLH1 (0.57) | NOD1GNPATFOLH1 | |
| SCHEMBL1711244 | 0.82 | FOLH1 (0.57) | NOD1GNPATFOLH1 | |
| SCHEMBL29511099 | 0.82 | FOLH1 (0.57) | NOD1GNPATFOLH1 | |
| SCHEMBL29563714 | 0.82 | FOLH1 (0.57) | NOD1GNPATFOLH1 | |
| SCHEMBL1711242 | 0.82 | FOLH1 (0.57) | NOD1GNPATFOLH1 | |
| SCHEMBL29405941 | 0.81 | FOLH1 (0.55) | NOD1GNPATFOLH1 | |
| SCHEMBL15757005 | 0.80 | DPP7 (0.58) | NOD1GNPATDPP8DPP7DPP4 | |
| SCHEMBL22717112 | 0.80 | SMN1; SMN2 (0.48) | NOD1GNPATFOLH1 | |
| SCHEMBL22717113 | 0.80 | SMN1; SMN2 (0.48) | NOD1GNPATFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139068-A1 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2026-05-21 | — | — | US | disclosed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139068-A1 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | ENTPD3, ENTPD1, ENTPD2 | NOD1 2095/4885GNPAT 652/4885FOLH1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.